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In this issue of PLOS Pathogens, Hutson and coworkers at the Centers for Disease Control
and Prevention (CDC) in Atlanta, USA describe a study with infectious variola virus that was
approved by the World Health Organization (WHO) Advisory Committee on Variola Virus
Research (ACVVR). Since such research is controversial, the editors felt that readers might
appreciate the following background information. Smallpox, a devastating disease caused by
variola virus, may have existed for 3,000 or more years. Although the pioneering observations
of Benjamin Jesty and Edward Jenner in late 18th century England provided the basis for con-
trol of smallpox by inoculation with the cowpox, the disease remained uncontrolled in every
continent and virtually every country more than 100 years later (Fig 1). Despite improved
methods of immunization with vaccinia virus, in 1967 the disease was still endemic in 33 coun-
tries and in that year alone caused an estimated 10–15 million cases, with 2 million deaths,
prompting the WHO to renew a world-wide surveillance and vaccination campaign. With the
participation of hundreds of thousands of health workers, the spread of variola virus was halted
and the last natural case of smallpox occurred in 1977 in Somalia. Smallpox was officially
declared eradicated by the WHO Global Commission for the Eradication of Smallpox in 1980.
The Global Commission made several recommendations including the retention of variola
virus stocks and complete viral genomes exclusively at WHO collaborating centers, which
were to be inspected periodically to ensure that storage is secure and that safe operating condi-
tions are maintained. All other laboratories were asked to destroy their variola virus stocks or
transfer them to one of the approved laboratories, which were identified as the CDC in
Atlanta, USA and the Research Institute of Virus Preparations in Moscow (later moved to Vec-
tor in Koltsovo, Russia). The Commission also recommended the establishment of the Com-
mittee on Orthopoxvirus Infections, which met annually from 1982 until 1988. The
Committee affirmed the importance of selected research on variola virus in the collaborating
centers. Thereafter, a WHO Ad Hoc Committee on Orthopoxviruses was established and
asked to consider whether the remaining variola virus stocks should be retained or destroyed.
This committee met in 1990, 1994, and 1999 and following debate in 1994 recommended that
all variola virus stocks held at the Collaborating Centers be destroyed. The World Health
Assembly (WHA) endorsed this recommendation in 1996 and a destruction date for June
1999 was set, with the intervening 3 years to allow the completion of any research with infec-
tious variola virus that was essential for public health benefit. However, in 1999, noting that all
essential work with variola virus was not yet complete, the WHA reviewed this recommenda-
tion and approved a further temporary retention of variola virus stocks so this research could
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be completed. The objectives of this research were to develop diagnostic tests, antiviral agents
and improved vaccines for smallpox. The ACVVR was established in 1999 to oversee this
research and has met every subsequent year to review progress towards these objectives, ensure
the safe storage and use of variola virus, and to consider further research proposals. In brief,
proposals for work with infectious variola virus from the two collaborating centers are submit-
ted to WHO and debated either by the whole ACVVR or a technical sub-committee that
includes poxvirus experts. Permission is either refused or given for a defined period and pur-
pose. Results of research are submitted at the ACVVR annual meeting, and a report is written
for the WHO Director General and Executive Board and published thereafter. If specific proj-
ects are incomplete, extensions can be requested.
Since the eradication of smallpox, the genome sequences of ~ 50 variola virus isolates have
been determined and the sequence deposited in public databases. These sequences have
enabled the development of sensitive and specific, polymerase chain reaction-based tests for
variola virus. In addition, variola virus neutralizing monoclonal antibodies have been isolated
and deployed to develop lateral flow tests for variola virus antigens. Smallpox was a disease
restricted to humans and variola virus was able to only infect man or, experimentally, pri-
mates. Despite the absence of a satisfactory animal model for smallpox, safer and better charac-
terized vaccines and two smallpox therapeutics (TPOXX and Tembexa) have been approved
by regulatory agencies.
In the present study, Hutson and colleagues developed a small animal model for smallpox
based on immunodeficient mice that were engrafted with part of the human immune system.
In these humanized mice, variola virus can replicate and spread, and although the disease
induced is not exactly the same as human smallpox, the model may be useful for testing new
therapeutic drugs for smallpox.
Looking forward, the 1996 WHA recommendation that stocks of variola virus should be
destroyed has not been revoked. Rather, its implementation has been delayed, and when last
debated by WHA additional research was authorized for several more years. However, the
ability to derive poxviruses from chemically synthesized genomes may undermine any deci-
sion to destroy existing isolates.
Fig 1. Timeline of significant events.
https://doi.org/10.1371/journal.ppat.1009911.g001
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